CellFE and Made Scientific Partner to Advance Non-Viral Gene Editing for T Cell Therapies
• CellFE and Made Scientific have formed a strategic collaboration to validate clinical-scale performance of CellFE's High Volume Cyva™ System for non-viral gene editing in T cell therapies.
• The partnership will evaluate two distinct manufacturing workflows: one using activated T cells for rapid autologous products, and another focusing on resting T cells to develop allogeneic "off-the-shelf" therapies.
• Results from the pilot program will be compiled into a comprehensive white paper to be shared with the cell and gene therapy community by October 2025.
Personalized Medicine Biomarkers Market Set to Reach $79.26 Billion by 2034, Driven by Precision Oncology and AI
• The global personalized medicine biomarkers market is projected to grow from $21.95 billion in 2024 to $79.26 billion by 2034, representing a CAGR of 13.7% as demand for precision healthcare solutions increases.
• Treatment selection dominates the market with 50.2% share, while oncology leads indication segments at 36.0%, reflecting the critical role of biomarkers in matching patients to targeted cancer therapies.
• North America currently holds 52.0% of market share, with the U.S. market alone expected to grow at 15.5% CAGR to reach $40.90 billion by 2034, driven by technological advancements and regulatory support.
© Copyright 2025. All Rights Reserved by MedPath